Arterys Wins FDA Clearance for Oncology Imaging Software

Arterys received 510(k) marketing clearance from the FDA for the Arterys Oncology AI suite of software, covering all solid tumors.

The software automates the segmentation of lung nodules and liver lesions, with accuracy equal to segmentations performed manually by experienced clinicians. The initial focus will be for liver MRI and CT scans as well as for lung CT scans, the company said.

The cloud based system enables “seamless collaboration” for clinicians, to provide second opinions from within the hospital or from outside experts," the company said.